Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -85.89 Million USD | -27.48% |
| 2022 | -67.37 Million USD | -24.77% |
| 2021 | -54 Million USD | -49.79% |
| 2020 | -36.05 Million USD | -39.85% |
| 2019 | -25.77 Million USD | -16.84% |
| 2018 | -22.06 Million USD | -7.22% |
| 2017 | -20.57 Million USD | -39.68% |
| 2016 | -14.73 Million USD | 37.05% |
| 2015 | -23.4 Million USD | -6.94% |
| 2014 | -21.88 Million USD | -14863.85% |
| 2013 | -146.24 Thousand USD | -32830.5% |
| 2012 | -444.11 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -27.35 Million USD | -11.18% |
| 2024 Q2 | -22.25 Million USD | 18.67% |
| 2024 Q3 | -24.94 Million USD | -12.09% |
| 2023 Q1 | -18.52 Million USD | 1.65% |
| 2023 Q3 | -22.53 Million USD | -17.21% |
| 2023 Q2 | -19.22 Million USD | -3.78% |
| 2023 Q4 | -24.6 Million USD | -9.19% |
| 2023 FY | -85.89 Million USD | -27.48% |
| 2022 Q4 | -18.83 Million USD | -22.7% |
| 2022 Q2 | -17.43 Million USD | -9.22% |
| 2022 Q1 | -15.96 Million USD | -29.18% |
| 2022 FY | -67.37 Million USD | -24.77% |
| 2022 Q3 | -15.35 Million USD | 11.94% |
| 2021 FY | -54 Million USD | -49.79% |
| 2021 Q3 | -13.24 Million USD | 13.9% |
| 2021 Q1 | -14.01 Million USD | -27.97% |
| 2021 Q2 | -15.38 Million USD | -9.79% |
| 2021 Q4 | -12.35 Million USD | 6.7% |
| 2020 FY | -36.05 Million USD | -39.85% |
| 2020 Q4 | -10.94 Million USD | -17.87% |
| 2020 Q3 | -9.28 Million USD | 2.97% |
| 2020 Q2 | -9.57 Million USD | 1.19% |
| 2020 Q1 | -9.68 Million USD | -30.03% |
| 2019 FY | -25.77 Million USD | -16.84% |
| 2019 Q4 | -7.45 Million USD | -29.99% |
| 2019 Q3 | -5.73 Million USD | 25.32% |
| 2019 Q2 | -7.67 Million USD | -55.85% |
| 2019 Q1 | -4.92 Million USD | 6.03% |
| 2018 Q2 | -6.67 Million USD | -87.89% |
| 2018 FY | -22.06 Million USD | -7.22% |
| 2018 Q4 | -5.24 Million USD | 20.61% |
| 2018 Q3 | -6.6 Million USD | 1.08% |
| 2018 Q1 | -3.55 Million USD | 13.06% |
| 2017 Q4 | -4.08 Million USD | 33.04% |
| 2017 Q3 | -6.09 Million USD | -17.94% |
| 2017 Q2 | -5.17 Million USD | 0.96% |
| 2017 Q1 | -5.22 Million USD | -43.28% |
| 2017 FY | -20.57 Million USD | -39.68% |
| 2016 Q3 | -3.8 Million USD | -3.1% |
| 2016 FY | -14.73 Million USD | 37.05% |
| 2016 Q1 | -3.58 Million USD | 29.54% |
| 2016 Q2 | -3.69 Million USD | -2.95% |
| 2016 Q4 | -3.64 Million USD | 4.28% |
| 2015 Q1 | -5.71 Million USD | -511.09% |
| 2015 Q2 | -7.86 Million USD | -37.71% |
| 2015 Q4 | -5.09 Million USD | -7.48% |
| 2015 Q3 | -4.73 Million USD | 39.78% |
| 2015 FY | -23.4 Million USD | -6.94% |
| 2014 Q1 | -228.94 Thousand USD | -284.0% |
| 2014 Q2 | -22.78 Million USD | -9851.38% |
| 2014 Q3 | -261.8 Thousand USD | 98.85% |
| 2014 Q4 | 1.38 Million USD | 630.69% |
| 2014 FY | -21.88 Million USD | -14863.85% |
| 2013 Q1 | -4583.00 USD | 95.87% |
| 2013 Q3 | -59.62 Thousand USD | -165.86% |
| 2013 Q4 | -59.62 Thousand USD | 0.0% |
| 2013 Q2 | -22.42 Thousand USD | -389.31% |
| 2013 FY | -146.24 Thousand USD | -32830.5% |
| 2012 Q4 | -111.02 Thousand USD | 0.0% |
| 2012 FY | -444.11 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 43.94% |
| Dynavax Technologies Corporation | -6.38 Million USD | -1244.42% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 6626.976% |
| Perrigo Company plc | -12.7 Million USD | -576.339% |
| Illumina, Inc. | -1.16 Billion USD | 92.602% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.433% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 80.656% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.005% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 106.325% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 22.308% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.173% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -115.492% |
| Waters Corporation | 642.23 Million USD | 113.374% |
| Biogen Inc. | 1.16 Billion USD | 107.398% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 66.686% |
| Evolus, Inc. | -61.68 Million USD | -39.248% |
| Adicet Bio, Inc. | -142.65 Million USD | 39.79% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 27.523% |
| bluebird bio, Inc. | -211.91 Million USD | 59.467% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 58.951% |
| FibroGen, Inc. | -284.23 Million USD | 69.78% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 106.927% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -92.575% |
| Homology Medicines, Inc. | -53.74 Million USD | -59.825% |
| Geron Corporation | -184.12 Million USD | 53.35% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 80.489% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 43.335% |
| Myriad Genetics, Inc. | -112 Million USD | 23.308% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 82.15% |
| Zoetis Inc. | 2.34 Billion USD | 103.664% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -58.513% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 110.89% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 151.236% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 102.373% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -103.547% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 76.55% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 68.893% |
| Verastem, Inc. | -87.36 Million USD | 1.685% |
| Nektar Therapeutics | -276.05 Million USD | 68.885% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 64.096% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 2.923% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 83.974% |
| OPKO Health, Inc. | -188.86 Million USD | 54.52% |
| Exelixis, Inc. | 207.76 Million USD | 141.342% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 134.399% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 180.926% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -80.813% |
| uniQure N.V. | -308.47 Million USD | 72.155% |
| Imunon, Inc. | -19.51 Million USD | -340.149% |
| Blueprint Medicines Corporation | -506.98 Million USD | 83.058% |
| Insmed Incorporated | -749.56 Million USD | 88.541% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 130.503% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 75.604% |
| TG Therapeutics, Inc. | 12.67 Million USD | 777.833% |
| Incyte Corporation | 597.59 Million USD | 114.373% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 88.705% |